Patient case (clinical description): A 63-year-old man comes to the clinic for recent unintentional weight loss. The patient also has epigastric discomfort after meals. He has no known medical problems and takes no medications. His blood pressure is 130/75 and pulse rate is 88/min. He is not febrile. Upper endoscopy shows a lesion in the stomach that shows typical features of diffuse-type adenocarcinoma presenting with signet ring cells that do not form glands.

Patient's own account: I went to the clinic because I had been losing so much weight that it was concerning. I'm a 63-year-old guy, and it is something rather unusual. I'm always suffering from stomachache after every meal. I've never been sick, and I don't take any medicine. The doctor took my blood pressure and told me it was 130/75, and my pulse rate was 88/min. I'm not febrile! I also had to do an endoscopy, and they found a lesion in my stomach that shows typical features of stomach cancer. I'm totally devastated...

Clinical trial: Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol

Eligibility criteria:
Inclusion Criteria:

          1. patients with gastric adenocarcinoma and colon cancer were diagnosed by histology and
             cytology, and there was a clear metastasis (TxNxM0);

          2. without any prior treatment (including surgery or radiotherapy and chemotherapy) in
             the I-III period, no distant metastasis, suitable for patients with surgical resection
             of the tumor.

          3. the age range of the patients is 18-60;

          4. systolic pressure 100-140mmHg; heart rate >60bpm;

          5. the patient's survival time should be longer than 3 months;

          6. without previous cardiovascular and cerebrovascular diseases, the atrioventricular
             block was excluded by the 24 hour dynamic electrocardiogram;

          7. ECOG score of 2 (that means the patient's bed time is less than 50%); Karnofsky score
             of 60% (that means patients have the basic activities and self-care ability);

          8. the basic biochemical examination results of patients with normal: white blood cell
             3000/ul; neutrophil 1500/ul 100000/ul; platelet count; total bilirubin < 1.5 x ULN;
             AST / ALT 2.5 x ULN without liver metastasis; < 5 x ULN liver metastasis; creatinine
             clearance rate of 1.5 x ULN;

          9. have the ability to understand and sign informed consent.

        Exclusion Criteria:

          1. pregnant or lactating women;

          2. patients with severe heart disease, kidney disease, metabolic disorders, bronchial
             asthma, cardiogenic shock, heart block (II-III degree atrioventricular block), or
             severe acute heart failure, sinus bradycardia.

          3. patients with epilepsy or psychotropic drugs and sedatives;

          4. patients with brain metastasis and bone marrow metastasis;

          5. participants in clinical trials of other drugs within 4 weeks;

          6. patients with a history of anaphylaxis with propranolol;

          7. patients treated with trastuzumab;

          8. patients with or reactive immunodeficiency, such as those with HIV infection;

          9. the uncontrollable situation in the group during the period (but not limited to these
             cases): according to the experimental scheme of medication, severe infection, due to
             mental illness or other social factors lead to the compliance requirements of
             patients;

         10. patients with atrioventricular block should be discontinued immediately and quit;

         11. the researchers believe there may be any increase in the risk of the subject or any
             interference with clinical trials.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 60 Years

Eligibility (NLI label): Contradiction